Muelle ER, et al. - In this prespecified analysis from the randomized, phase III SYNERGY II study, a total of 1794 subjects of age ≥18 years were assessed to investigate the safety and efficiency of the combination of mirabegron and solifenacin vs each monotherapy among older candidates with overactive bladder (OAB). About 47.2% of individuals were observed with ≥1 treatment-emergent adverse events (TEAE). Researchers recorded an increase in mean pulse rate of >1 bpm from baseline in the younger age groups with combination therapy and mirabegron (monotherapy) only. Overall, they concluded mirabegron and solifenacin combination therapy, well-tolerated and efficient for subjects with OAB symptoms irrespective of their age.